FR14C0051I1 - - Google Patents

Info

Publication number
FR14C0051I1
FR14C0051I1 FR14C0051C FR14C0051I1 FR 14C0051 I1 FR14C0051 I1 FR 14C0051I1 FR 14C0051 C FR14C0051 C FR 14C0051C FR 14C0051 I1 FR14C0051 I1 FR 14C0051I1
Authority
FR
France
Prior art keywords
dialkyl fumarates
transplantation medicine
cyclosporines
pellets
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7888396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0051(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0051I1 publication Critical patent/FR14C0051I1/fr
Application granted granted Critical
Publication of FR14C0051I2 publication Critical patent/FR14C0051I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
FR14C0051C 1998-11-19 2014-06-25 Dialkylfumarates pour le traitement de maladies autoimmunes Active FR14C0051I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19853487A DE19853487A1 (de) 1998-11-19 1998-11-19 Verwendung von Dialkylfumaraten
PCT/EP1999/008215 WO2000030622A2 (de) 1998-11-19 1999-10-29 Verwendung von dialkylfumaraten zur behandlung von host-versus-graft reaktionen und von autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
FR14C0051I1 true FR14C0051I1 (pl) 2014-08-08
FR14C0051I2 FR14C0051I2 (fr) 2019-01-18

Family

ID=7888396

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0051C Active FR14C0051I2 (fr) 1998-11-19 2014-06-25 Dialkylfumarates pour le traitement de maladies autoimmunes

Country Status (34)

Country Link
US (9) US6509376B1 (pl)
EP (1) EP1131065B1 (pl)
JP (7) JP2002530324A (pl)
CN (2) CN1182844C (pl)
AT (1) ATE242633T1 (pl)
BE (1) BE2014C040I2 (pl)
BG (1) BG64837B1 (pl)
BR (1) BR9914606A (pl)
CA (1) CA2346438C (pl)
CY (1) CY2014027I1 (pl)
CZ (1) CZ299409B6 (pl)
DE (2) DE19853487A1 (pl)
DK (1) DK1131065T3 (pl)
EE (1) EE04389B1 (pl)
ES (1) ES2195664T3 (pl)
FR (1) FR14C0051I2 (pl)
HK (1) HK1042242B (pl)
HU (2) HU226689B1 (pl)
IL (2) IL142728A0 (pl)
LT (1) LTC1131065I2 (pl)
LU (1) LU92488I2 (pl)
ME (1) ME00731B (pl)
MX (1) MXPA01005007A (pl)
NO (3) NO333257B1 (pl)
NZ (1) NZ510247A (pl)
PL (2) PL226074B1 (pl)
PT (1) PT1131065E (pl)
RS (1) RS49995B (pl)
RU (1) RU2215524C2 (pl)
SI (1) SI1131065T1 (pl)
SK (1) SK285601B6 (pl)
TR (1) TR200101204T2 (pl)
WO (1) WO2000030622A2 (pl)
ZA (1) ZA200202335B (pl)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US6912052B2 (en) * 2000-11-17 2005-06-28 Cymer, Inc. Gas discharge MOPA laser spectral analysis module
JP2004523511A (ja) * 2001-01-12 2004-08-05 フーマファーム アーゲー フマル酸アミド類
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US20050259709A1 (en) * 2002-05-07 2005-11-24 Cymer, Inc. Systems and methods for implementing an interaction between a laser shaped as a line beam and a film deposited on a substrate
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
WO2004112773A1 (fr) * 2003-04-24 2004-12-29 Shin-Jen Shiao Compositions pharmaceutiques utilisees pour le traitement de maladie immune et amelioration
US7277188B2 (en) * 2003-04-29 2007-10-02 Cymer, Inc. Systems and methods for implementing an interaction between a laser shaped as a line beam and a film deposited on a substrate
DE10360869A1 (de) * 2003-09-09 2005-04-07 Fumapharm Ag Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
AU2004269903B2 (en) 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (de) * 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US6894785B2 (en) * 2003-09-30 2005-05-17 Cymer, Inc. Gas discharge MOPA laser spectral analysis module
US6873418B1 (en) 2003-09-30 2005-03-29 Cymer, Inc. Optical mountings for gas discharge MOPA laser spectral analysis module
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
PT2801354T (pt) * 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
US20080004344A1 (en) * 2004-11-10 2008-01-03 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
US7653095B2 (en) * 2005-06-30 2010-01-26 Cymer, Inc. Active bandwidth control for a laser
EP1915334A2 (en) * 2005-07-07 2008-04-30 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP2186819A1 (en) 2005-07-07 2010-05-19 Aditech Pharma AG Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
JP2009510137A (ja) * 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
US7317179B2 (en) * 2005-10-28 2008-01-08 Cymer, Inc. Systems and methods to shape laser light as a homogeneous line beam for interaction with a film deposited on a substrate
US7679029B2 (en) * 2005-10-28 2010-03-16 Cymer, Inc. Systems and methods to shape laser light as a line beam for interaction with a substrate having surface variations
WO2008096271A2 (en) * 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
EP2680007A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
DE102008030023A1 (de) 2008-06-16 2009-12-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
RU2554347C2 (ru) * 2008-08-19 2015-06-27 Ксенопорт, Инк. Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения
UA112975C2 (uk) 2009-01-09 2016-11-25 Форвард Фарма А/С Фармацевтичний склад, що містить в матриці, яка піддається ерозії, один або більше ефірів фумарової кислоти
EP2424357A4 (en) 2009-04-29 2012-10-10 Biogen Idec Inc TREATMENT OF NERVOUS GENERATION AND NERVE IGNITION
PL2533634T3 (pl) 2010-02-12 2016-04-29 Biogen Ma Inc Neuroprotekcja w chorobach demielinizacyjnych
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
WO2011116091A1 (en) 2010-03-17 2011-09-22 Novartis Ag Dispenser
HUE035098T2 (en) 2010-04-16 2018-05-02 Biogen Ma Inc Anti-VLA4 Antibodies
SG195049A1 (en) * 2011-05-26 2013-12-30 Biogen Idec Inc Methods of treating multiple sclerosis and preserving and/or increasing myelin content
CN103649041A (zh) 2011-06-08 2014-03-19 比奥根艾迪克Ma公司 制备高纯度和结晶的富马酸二甲酯的方法
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130216615A1 (en) * 2012-02-07 2013-08-22 David Goldman Pharmaceutical Compositions Containing Dimethyl Fumarate
WO2013119791A1 (en) * 2012-02-07 2013-08-15 Xenoport, Inc. Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
EP2852569B1 (en) * 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2014031844A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US9597292B2 (en) 2012-08-22 2017-03-21 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CN103483194B (zh) * 2012-11-30 2016-03-09 杨寅柯 一种2-氟代富马酸酯(结构式i)及其制备方法及应用
US20140171504A1 (en) 2012-12-14 2014-06-19 Georgia Regents Research Institute, Inc. Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
EP2934503B1 (en) 2012-12-21 2019-04-10 Biogen MA Inc. Deuterium substituted fumarate derivatives
KR101379427B1 (ko) * 2013-02-13 2014-03-28 경북대학교병원 디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물
SG10201707543PA (en) 2013-03-14 2017-11-29 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
KR20210139485A (ko) 2013-08-26 2021-11-22 에프더블유피 아이피 에이피에스 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물
CN104415026A (zh) * 2013-08-31 2015-03-18 成都渊源生物科技有限公司 氘代富马酸衍生物在治疗多发性硬化症中的应用
WO2015035184A1 (en) 2013-09-06 2015-03-12 Xenoport, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
CN104434904B (zh) * 2013-09-22 2018-09-04 深圳翰宇药业股份有限公司 一种复方微丸胶囊的制备方法及其制备的复方微丸胶囊
KR20160085757A (ko) * 2013-09-27 2016-07-18 테바 파마슈티컬 인더스트리즈 리미티드 다발성 경화증의 치료를 위한 라퀴니모드 병용 치료
LT3079666T (lt) * 2013-12-12 2021-03-25 Almirall S.A. Farmacinės kompozicijos, apimančios dimetilfumaratą
EP3079663A1 (en) 2013-12-13 2016-10-19 Biogen MA Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3650042A1 (en) 2014-03-14 2020-05-13 Biogen MA Inc. Dimethyl fumarate and vaccination regimens
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
CN104027311A (zh) * 2014-05-09 2014-09-10 万特制药(海南)有限公司 一种含有富马酸二甲酯的肠溶缓释微丸
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
DE102014015314A1 (de) * 2014-10-17 2016-04-21 Ppm-Medical Holding Gmbh Mittel zur unterstützenden Immunmodulation
MA40985A (fr) 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
CN104490849A (zh) * 2014-11-24 2015-04-08 广东东阳光药业有限公司 一种高密度的富马酸二甲酯肠溶颗粒及其制备方法
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102283582B1 (ko) 2014-12-23 2021-07-30 한미약품 주식회사 푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
WO2016126540A1 (en) * 2015-02-02 2016-08-11 Enspire Group LLC Stabilized dialkyl fumarate compositions
ES2879611T3 (es) * 2015-02-08 2021-11-22 Alkermes Pharma Ireland Ltd Composiciones de profármaco de monometilfumarato
AU2016231883B2 (en) * 2015-03-17 2019-03-07 Hetero Labs Limited Pharmaceutical compositions of dimethyl fumarate
DK3273951T3 (da) 2015-03-27 2020-11-02 Symbionyx Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af psoriasis
US10085961B2 (en) 2015-06-01 2018-10-02 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
MA42196A (fr) 2015-06-17 2018-04-25 Biogen Ma Inc Particules de fumarate de diméthyle et leurs compositions pharmaceutiques
US10213411B2 (en) 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017056107A1 (en) 2015-09-28 2017-04-06 Natco Pharma Ltd Pharmaceutical compositions of dimethyl fumarate
WO2017060420A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
DE102016103242A1 (de) 2016-02-24 2017-08-24 Flexopharm Brain Gmbh & Co. Kg Mittel zur unterstützenden Immunmodulation
MX2018005345A (es) * 2015-10-28 2018-08-14 Sun Pharmaceutical Ind Ltd Composiciones farmaceuticas de dimetil fumarato.
US10463642B2 (en) 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
CN106265621B (zh) * 2016-09-19 2019-05-17 苏州大学 富马酸二甲酯在制备预防和治疗移植物抗宿主病及移植物抗白血病药物中的应用
GR1009149B (el) 2016-10-25 2017-10-31 Φαρματεν Αβεε Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων
TR201616998A1 (en) * 2016-11-23 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi DELAYED RELEASE DOSING FORMS WITH DIMETHYL FUMARATE
DE102017105036A1 (de) 2017-03-09 2018-09-13 Flexopharm Brain Gmbh & Co. Kg Mittel zur Anwendung bei der Behandlung der Dyslipidämie
KR20200018458A (ko) 2017-06-23 2020-02-19 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학 조성물
MX2021012441A (es) 2019-05-31 2022-10-07 Curacle Co Ltd Tableta enterica que contiene fumarato de dimetilo.
RU2742745C1 (ru) * 2019-09-24 2021-02-10 Акционерное общество "Исследовательский Институт Химического Разнообразия" Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
MX2022010962A (es) 2020-03-06 2022-10-07 Actelion Pharmaceuticals Ltd Metodos para ralentizar la perdida de volumen cerebral.
CN111418675A (zh) * 2020-04-23 2020-07-17 王坤全 一种幼儿保健茶
WO2021144478A2 (en) 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
KR20220133807A (ko) 2021-03-25 2022-10-05 주식회사 큐라클 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물
CA3221343A1 (en) 2021-10-11 2023-04-20 Allitia DIBERNARDO Methods of treating multiple sclerosis
CA3220702A1 (en) 2022-02-11 2023-08-17 Actelion Pharmaceuticals Ltd Methods of slowing an increase in brain ventricular volume
CN115590831A (zh) * 2022-10-26 2023-01-13 力品药业（厦门）股份有限公司（Cn） 一种富马酸二甲酯缓释微片及其制备方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1972109U (de) 1965-10-20 1967-11-09 Qualitrol Corp Schnellventil zum schutz elektrischer geraete.
DE1618162B1 (de) 1967-05-20 1971-05-19 Basf Ag Verfahren zur Herstellung con Cyclohexan-1.2.3.4.5.6-hexan-carbonsäure
US3832287A (en) 1972-03-02 1974-08-27 Lilly Co Eli Dipeptide antibiotic and method for the production thereof
DE2212369A1 (de) 1972-03-15 1973-09-20 Basf Ag Cyclohexanhexacarbonsaeure
DE2530372A1 (de) * 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
DE2621214C3 (de) * 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
DE2840498C2 (de) * 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
DE3127432A1 (de) 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61194020A (ja) 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
GB2176999B (en) 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
DE3531597A1 (de) 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5214196A (en) 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
AU1271592A (en) 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
CA2164837A1 (en) 1993-06-08 1994-12-22 Raymond K. Brown Therapeutic compositions and methods of use
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US7888458B1 (en) 1993-11-30 2011-02-15 John B. Harley Diagnostics and therapy of epstein-barr virus in autoimmune disorders
US5407772A (en) 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
AU1945495A (en) 1994-03-16 1995-10-03 Novo Nordisk A/S Acid addition salts of 2,3,4,5-tetrahydro-1h-3-benzazepine compounds
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
IL110380A0 (en) 1994-07-20 1994-10-21 Agis Ind 1983 Ltd Antiviral topical pharmaceutical compositions
US5589504A (en) 1994-07-26 1996-12-31 Cornell Research Foundation, Inc. Treatment of newborn jaundice
CN1125141A (zh) 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
US6011000A (en) 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
CA2226915A1 (en) 1995-09-13 1997-03-20 Yoshikazu Ohta Immunosuppressant
JPH1067658A (ja) * 1995-09-13 1998-03-10 Takeda Chem Ind Ltd 免疫抑制剤
JP4004567B2 (ja) 1996-02-14 2007-11-07 アステラス製薬株式会社 Ｗｂ２６６３ｂ物質を含有する免疫抑制剤
KR970064620A (ko) * 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
PT895981E (pt) 1996-04-22 2001-05-31 Shionogi & Co Compostos de terfenilo e medicamentos contendo os mesmos
IL127166A0 (en) 1996-05-22 1999-09-22 Univ Alberta Type-2 chemokine binding proteins and methods of use therefor
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
EP1611885A1 (en) 1996-07-26 2006-01-04 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
DE19651551C2 (de) * 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
WO1998027970A2 (en) 1996-12-24 1998-07-02 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
JP2001521002A (ja) 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． 脳の代謝機能不全のための栄養補充剤
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
EP1272614B1 (en) 2000-02-11 2007-08-15 Philadelphia Health and Education Corporation Differentiation of bone marrow cells into neuronal cells and uses therefor
WO2002002190A2 (en) 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
JP2004523511A (ja) 2001-01-12 2004-08-05 フーマファーム アーゲー フマル酸アミド類
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
CA2463624A1 (en) 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
EP1477166B1 (de) 2003-04-28 2006-08-23 Biofrontera Bioscience GmbH Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
AU2004269903B2 (en) 2003-09-09 2010-09-02 Biogen International Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
US20050096369A1 (en) 2003-11-04 2005-05-05 Hoang Ba X. Compositions and methods for treating cellular proliferation disorders
MX2007000142A (es) 2004-06-30 2007-03-26 Combinatorx Inc Metodos y reactivos para el tratamiento de desordenes metabolicos.
PT2801354T (pt) 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
EP1812374A1 (en) 2004-11-10 2007-08-01 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
AU2005306399B2 (en) 2004-11-19 2012-02-09 Biogen Ma Inc. Treatment for multiple sclerosis
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
EP2680007A1 (en) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2 screening assays and related methods and compositions
WO2008096271A2 (en) 2007-02-08 2008-08-14 Ralf Gold Neuroprotection in demyelinating diseases
EP2424357A4 (en) 2009-04-29 2012-10-10 Biogen Idec Inc TREATMENT OF NERVOUS GENERATION AND NERVE IGNITION

Also Published As

Publication number Publication date
EE200100266A (et) 2002-12-16
HU226689B1 (en) 2009-06-29
DE59905954D1 (de) 2003-07-17
US20090182047A1 (en) 2009-07-16
US6509376B1 (en) 2003-01-21
HUP0103182A3 (en) 2002-02-28
CA2346438C (en) 2006-10-03
CZ299409B6 (cs) 2008-07-16
US7612110B2 (en) 2009-11-03
JP2005097323A (ja) 2005-04-14
SK285601B6 (sk) 2007-04-05
ME00731B (me) 2008-09-29
FR14C0051I2 (fr) 2019-01-18
US20030018072A1 (en) 2003-01-23
MXPA01005007A (es) 2002-04-24
WO2000030622A3 (de) 2000-11-02
US7320999B2 (en) 2008-01-22
US20110293711A1 (en) 2011-12-01
JP5828614B2 (ja) 2015-12-09
BR9914606A (pt) 2001-07-03
NO20011242D0 (no) 2001-03-12
JP2017226681A (ja) 2017-12-28
CA2346438A1 (en) 2000-06-02
NZ510247A (en) 2003-10-31
JP2002530324A (ja) 2002-09-17
CZ2001939A3 (cs) 2002-05-15
ES2195664T3 (es) 2003-12-01
WO2000030622A2 (de) 2000-06-02
PL226074B1 (pl) 2017-06-30
BG105396A (en) 2001-12-29
BG64837B1 (bg) 2006-06-30
TR200101204T2 (tr) 2001-09-21
NO2014016I1 (no) 2014-06-26
CN1615839A (zh) 2005-05-18
RU2215524C2 (ru) 2003-11-10
NO20121479L (no) 2001-05-18
US20070248663A1 (en) 2007-10-25
US20090181085A1 (en) 2009-07-16
EP1131065A2 (de) 2001-09-12
SI1131065T1 (en) 2003-10-31
ZA200202335B (en) 2003-08-27
PT1131065E (pt) 2003-10-31
EE04389B1 (et) 2004-12-15
YU29901A (sh) 2003-04-30
JP2012255020A (ja) 2012-12-27
AU752733B2 (en) 2002-09-26
ATE242633T1 (de) 2003-06-15
US20130004526A1 (en) 2013-01-03
CN1182844C (zh) 2005-01-05
EP1131065B1 (de) 2003-06-11
US20140066505A1 (en) 2014-03-06
LTC1131065I2 (lt) 2019-05-27
BE2014C040I2 (pl) 2019-03-13
DE19853487A1 (de) 2000-05-25
DK1131065T3 (da) 2003-08-25
JP2019123738A (ja) 2019-07-25
JP2016047830A (ja) 2016-04-07
CY2014027I2 (el) 2015-12-09
PL348147A1 (en) 2002-05-06
LU92488I2 (fr) 2015-11-02
US7915310B2 (en) 2011-03-29
US8759393B2 (en) 2014-06-24
US20070248662A1 (en) 2007-10-25
IL142728A0 (en) 2002-03-10
NO2014016I2 (no) 2018-08-20
CY2014027I1 (el) 2015-12-09
NO333257B1 (no) 2013-04-22
IL142728A (en) 2006-12-10
HK1042242B (zh) 2005-08-19
US7619001B2 (en) 2009-11-17
US8524773B2 (en) 2013-09-03
PL205948B1 (pl) 2010-06-30
RS49995B (sr) 2008-09-29
HK1042242A1 (en) 2002-08-09
HUP0103182A2 (hu) 2002-01-28
SK5762001A3 (en) 2002-03-05
JP2009256384A (ja) 2009-11-05
CN1325302A (zh) 2001-12-05
AU1157200A (en) 2000-06-13
NO20011242L (no) 2001-05-18
US7803840B2 (en) 2010-09-28
HUS1400034I1 (hu) 2018-11-28

Similar Documents

Publication Publication Date Title
BE2014C040I2 (pl)
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
HK1040623A1 (en) The use of fumaric acid derivatives in transplantation medicine.
MXPA02007932A (es) Analogos de nucleosidos con base biciclica modificada con carboxamidina.
FI962154A (fi) Koostumus terapeuttisten tuotteiden in vivo valmistusta varten
EP0783299A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
HK1036969A1 (en) Compounds and compositions for delivering active agents
CA2189250A1 (en) Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
EP0663835A1 (en) USE OF PARATHORMONE, ITS BIOLOGICALLY ACTIVE FRAGMENTS AND RELATED PEPTIDES FOR THE TREATMENT OF PREGNANCY PROBLEMS.
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
HK1045456B (zh) 病毒炎性調節蛋白在阻斷異種移植排斥中的治療新用途
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
GB9727424D0 (en) Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
IT1254742B (it) Impiego della beta-endorfina quale farmaco immunosoppressore nei trapianti d'organo
MX9600383A (es) W-ifn como un agente anti-hiv.
YU61302A (sh) Analozi nukleozida sa modifikovanom karboksamidinskom bicikličnom bazom